Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

emergent biosolutions berna gmbh - haemagglutininum influenzae di tipo a (h1n1), neuraminidasum inactivatum (virus-stamm a/california/7/2009 x-181) - siringa preriempita - haemagglutininum influenzae di tipo a (h1n1) e neuraminidasum inactivatum (virus-stamm a/california/7/2009 x-181) 7.5 µg, adjuvans mf59: squalenum, polysorbatum 80, sorbitani trioleas, natrii citras dihydricus, acido citricum monohydricum, excipiens: natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesio chloridum hexahydricum, calcio chloridum dihydricum, acqua q.s. la sospensione 0,5 ml. - vaccino influenzale pandemico - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

emergent biosolutions berna gmbh - haemagglutininum influenzae di tipo a (h1n1), neuraminidasum inactivatum (virus-stamm a/california/7/2009 x-181) - mehrfachdosenbehältnis - haemagglutininum influenzae di tipo a (h1n1) e neuraminidasum inactivatum (virus-stamm a/california/7/2009 x-181) 7.5 µg, adjuvans mf59: squalenum, polysorbatum 80, sorbitani trioleas, natrii citras dihydricus, acido citricum monohydricum, excipiens: natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesio chloridum hexahydricum, calcio chloridum dihydricum, conserv.: thiomersalum 50 µg, acqua q.s. la sospensione 0,5 ml. - vaccino influenzale pandemico - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus pennino-104 ), haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lignaggio)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus nib-104 ) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (ceppo del virus a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (ceppo del virus a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus ivr-186), haemagglutininum influenzae b (virus del ceppo b/colorado/06/2017-come: reassortant virus nymc bx-69a derivata da b/veneto/15/2016 (victoria lignaggio)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: reassortant virus wild type derived from b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - impfstoffe

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190), haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-come: reassortant virus a/kansas/14/2017, nymc x-327), haemagglutininum influenzae b (virus stamm b/colorado/06/2017-come: reassortant virus b/veneto/15/2016 nymc bx-69a) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortant virus a/kansas/14/2017, nymc x-327) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: natrii citras dihydricus max. 1 mg, cetrimidum max. 15 µg, formaldehydum max. 10 µg, gentamicini sulfas max. 1 ng, tylosini tartras nihil, hydrocortisonum nihil, polysorbatum 80 nihil, ovalbuminum max. 0.1 µg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190), haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-come: reassortant virus a/kansas/14/2017, nymc x-327), haemagglutininum influenzae b (virus stamm b/colorado/06/2017-come: reassortant virus b/veneto/15/2016 nymc bx-69a) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortant virus a/kansas/14/2017, nymc x-327) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: natrii citras dihydricus max. 1 mg, cetrimidum max. 15 µg, formaldehydum max. 10 µg, gentamicini sulfas max. 1 ng, tylosini tartras nihil, hydrocortisonum nihil, polysorbatum 80 nihil, ovalbuminum max. 0.1 µg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (virus souche un/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b (virus souche b/brisbane/60/2008) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus souche un/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus souche b/brisbane/60/2008) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, il resto: formaldehydum max. 100 µg, octoxinolum-9 max. 500 µg, ovalbuminum max. 0,05 µg sintetiche, no, neomycinum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b ), haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lignaggio)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b ) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/brisbane/60/2008 (victoria lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (ceppo del virus a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (ceppo del virus a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus ivr-186), haemagglutininum influenzae b (virus del ceppo b/colorado/06/2017-come: reassortant virus nymc bx-69a derivata da b/veneto/15/2016) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, residui: formaldehydum max. 30 µg, octoxinolum-9 max. 200 µg, neomycinum max. 7.5 pg, ovalbuminum max. 50 ng, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - impfstoffe